Serum levels of matrix metaloproteinase 2 (MMP-2), matrix metaloproteinase 9 (MMP-9) and tissue inhibitor of metaloproteinase 2 (TIMP-2) in children and adolescents with growth hormone deficiency;Ocena stȩżenia metaloproteinazy macierzy pozakomórkowej 2 (MMP-2), metaloproteinazy macierzy pozakomórkowej 9 (MMP-9) i tkankowego inhibitora metaloproteinazy 2 (TIMP-2) u dzieci i młodziezy z niedoborem hormonu wzrostu

Endokrynologia, Diabetologia i Choroby Przemiany Materii Wieku Rozwojowego

Volumn 12, Issue 4, 2006, Pages 257-260

  Szczepańska Kostro, Jolanta ^a   Kowalewski, Marek ^a   Urban, Mirosława ^a   Gardziejczyk, Maria ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Children and adolescents; Growth hormone deficiency; Metaloproteinases

Indexed keywords

GELATINASE A; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 2; BIOLOGICAL MARKER; HUMAN GROWTH HORMONE;

ADOLESCENT; ARTICLE; BODY HEIGHT; BODY MASS; BODY SURFACE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GROWTH HORMONE DEFICIENCY; HUMAN; MALE; PROTEIN BLOOD LEVEL; BLOOD; DRUG ANTAGONISM; DWARFISM; ENZYMOLOGY; EXTRACELLULAR MATRIX; GROWTH DISORDER; PHYSIOLOGY; REFERENCE VALUE; UPREGULATION;

ADOLESCENT; BIOLOGICAL MARKERS; CHILD; DWARFISM; EXTRACELLULAR MATRIX; FEMALE; GROWTH DISORDERS; HUMAN GROWTH HORMONE; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; REFERENCE VALUES; TISSUE INHIBITOR OF METALLOPROTEINASE-2; UP-REGULATION;

EID: 33845947197     PISSN: 1234625X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Berglund L., Thomas A.M.: Editorial: Growth hormone and cardiovascular disease: an area in rapid growth. J. Clin. Endocrinol. Metab., 2001, 86, 1871-1873.
2. Colao A., Di Somma C., Salerno M i wsp.: The cardiovascular risk of GH-deficient adolescents. J. Clin. Endocrinol. Metab., 2002, 87, 3650-3655.
3. Rosen T., Bengtsson B.-A.: Premature mortallity due to cardiovascular disease in hypopituitarism. Lancet, 1990, 336, 285-288.
4. Bengtsson B., Christiansen J., Cuneo R. i wsp.: Cardiovascular effects of GH. J. Endocrinol., 1997, 152, 1-3.
5. Sacca L., Atteolini A., Marzullo P i wsp.: Growth hormone and the heart. Endocr. Rev., 1994, 15, 555-573.
6. Lombardini G., Colao A., Marzullo P i wsp.: Is growth hormone bad for your heart: cardiovascular impact of GH deficiency and excess. J Endocrinol., 1997, 155, S33-S37.
7. Sesmilo G., Biller B., Llevadot J. i wsp.: Effects of growth hormone administration on inflammatory and other cardiovascular risk factors in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann. Intern. Med., 2000, 133, 111-122.
8. Carrol P., Christ E., Bengtsson B. i wsp.: Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. J. Clin. Endocrinol. Metab., 1998, 83, 382-395.
9. Egeblad M., Werb Z.: New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer, 2002, 2, 161-174.
10. Kotulska-Wolwender K., Larysz-Brysz M., Fus Z. i wsp.: Metaloproteinazy macierzy pozakomórkowej - perspektywy ich wykorzystania w medycynie. Wiad. Lek., 2002, 55, 463-471.
11. Hamacher S., Matern S., Roeb E.: Extracellular matrix - from basic research to clinical implications. Dtsch. Med. Wochenschr., 2004, 129, 1976-1980.
12. Doherty T.M., Asotra K., Pei D. i wsp.: Therapeutic developments in matrix metalloproteinase inhibition. Exp. Opin. Therapeutic Patients, 2002, 12, 655-697.
13. Hayakawa T.: Multiple function of tissue inhibitors (TIMPs) of metalloproteinases: a new aspect involving osteoclastic bone resorption. J. Bone Miner. Metab., 2002, 20, 1-13.
14. Gomez D.E., Alonso D.F., Yoshiji H., Thorgeirsson U.P.: Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur. J. Cell Biol., 1997, 74, 111-122.
15. Shah P.K., Galis Z.S.: Matrix metalloproteinase hypothesis of plaque rupture: players keep piling up but questions remain. Circulation, 2001, 104, 1878-1880.
16. Galis Z.S., Khatri J.J.: Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ. Res., 2002, 90, 251-262.
17. George S.J.: Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis. Exp. Opin. Inv. Drugs., 2000, 9, 993-1007.
18. Creemers E.E., Cleutjens J.P., Smits J.F., Daemen M.J.: Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ. Res., 2001, 89, 201-210.
19. Ortega N., Behonick D., Stickens D., Werb Z.: How proteases regulate bone morfogenesis. Ann. N.Y. Acad. Sci., 2003, 995, 109-116.
20. Wang W., Schulze C.J., Suarez-Pinzon i wsp.: Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation, 2002, 106, 1543-1549.
21. Galis Z.S., Sukhova G.K., Lark M.W i wsp.: Increased experssion of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest., 1994, 94, 2493-2503.
22. Shah P.K.: Plague disruption and thrombosis: potential role of inflammation and infection. Cardiol. Rev., 2000, 8, 31-39.
23. Kai H., Ikeda H., Yasukawa H. i wsp.: Peripheral blood levels of matrix metalloproteinases-2 and 9 are elevated in patients with acute coronary syndromes. J. Am. Coll. Cardiol., 1998, 32, 368-372.
24. Mun-Bryce S., Rosenberg G.A.: Matrix metalloproteinases in cerebrovascular disease. J. Cereb. Blood Flow Metab., 1998, 18, 1163-1172.
25. Randeva H.S., Lewandowski K.C., Komorowski J. i wsp.: Growth hormone replacement decreases plasma levels of matrix metalloproteinases (2 and 9) and vascular endothelial growth factor in growth hormone-deficient individuals. Circulation, 2004, 109, 2405-2410.
26. Wong T.T., Sethi C., Daniels J.T. i wsp.: Matrix metalloproteinases in disease and repair processes in the anterior segment. Surv. Ophtalmol., 2002, 47, 239-256.
27. Anne-Valerie R., Christelle D., Yannick F. i wsp.: Human growth hormone stimulates proteinase activities of rabbit bone cells via IGF-1. Biochem. Biophys. Res. Commun., 2000, 268, 875-881.
28. Wilson M.J., Sellers R.G., Wiehr C. i wsp.: Expression of matrix metalloproteinase-2 and -9 and their inhibitors, tissue inhibitor of metalloproteinase-1 and -2, in primary cultures of human prostatic stromal and epithelial cells. J. Cell. Physiol., 2002, 191, 208-216.
29. Lupia E., Elliot S.J., Lenz O. i wsp.: IGF-1 decreases collagen degradation in diabetic NOD mesangial cells: implications for diabetic nephropathy. Diabetes, 1999, 48, 1638-1644.
30. Pattison S.T., Melrose J., Ghosh P. i wsp.: Regulation of gelatinase-A (MMP-2) production by ovine intervertebral disc nucleus pulposus cells grown in alginate bead culture by transforming growth factor-beta(1) and insulin like growth factor-1. Cell Biol. Int., 2001, 25, 679-689.
31. Punglia R.S., Lu M., Hsu J. i wsp.: Regulation of vascular endothelial growth factor expression by insulin like growth factor I. Diabetes, 1997, 46, 1619-1626.
32. Sesmilo G., Biller B.M., Llevadot J. i wsp.: Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency: a randomized, controlled clinical trial. Ann. Intern. Med., 2000, 133, 111-122.
33. Haffner S.M., Greenberg A.S., Weston W.M. i wsp.: Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation, 2002, 106, 679-684.
34. Boloumie A., Sengenes C., Portolan B. i wsp.: Adipocyte produces matrix metalloproteinases 2 and 9: involvement in adipose differentiation. Diabetes, 2001, 50, 2080-2086.
35. Lijen H.R., Maquoi E., Hansen LB. i wsp.: Matrix metalloproteinases inhibition impairs adipose tissue development in mice. Arterioscler. Thromb. Vasc. Biol., 2002, 22, 374-379.